A simple regimen to treat basal and squamous cell skin cancer is an unmet clinical need in dermatology.
SkinJect provides a solution.
Between 40 and 50 percent of Americans who live to age 65 will experience basal cell carcinoma or squamous cell carcinoma at least once.
There are approximately two million biopsy-confirmed patients diagnosed with basal cell carcinoma annually – accounting for nearly 80 percent of all skin cancer cases.
A large majority of patients treated for basal cell carcinoma will experience a recurrence.
SkinJect is a novel dissolvable microneedle patch being developed as a treatment for basal cell and squamous cell skin cancer.
A less painful, less invasive way to treat skin cancer, SkinJect may also lower the likelihood of recurrence.
SkinJect is a development stage company actively working to advance the technologies and related patent portfolio to commercial standards. There is no assurance that the Microneedle Array platform or associated products will be successfully commercialized. The future success of the business will depend on the Company’s ability to secure clearance to market products from regulatory authorities and for prospective customers to purchase products. Further, the market for treatment of basal cell carcinoma and other disease states is highly competitive.